AKT1 and acute lymphoblastic leukemia: Although preclinical studies have demonstrated that inhibition of PI3K/Akt/mTOR axis could be an effective strategy for targeted therapy of T-ALL [47, 48], it is still unclear which is the best target in this highly complex and branched signaling network.